An evaluation of the performance of OraQuick ADVANCE Rapid HIV-1/2 Test in a high-risk population attending genitourinary medicine clinics in East London, UK.
To date, no data have been published on the use of OraQuick ADVANCE Rapid HIV-1/2 Test (OraQuick) in the UK. We report preliminary findings of an ongoing evaluation of OraQuick in UK genitourinary (GU) medicine clinics. A total of 820 samples from patients in high-risk groups for HIV were tested with OraQuick and results were compared with standard HIV antibody testing. HIV prevalence (enzyme immunoassay [EIA]) was 5.73%, sensitivity of OraQuick was 93.64% (95% CI 82.46-98.66%), specificity 99.87% (99.28-100%), positive predictive value 97.78% (88.27-99.94%) and negative predictive value 99.61% (98.87-99.92%). This includes three false-negatives considered to be due to observer error and now rectified by further training. This has increased test sensitivity to 100%. Our observed test performance of OraQuick compares well with EIA and with other rapid tests. We believe that simple, non-invasive antibody detection tests such as OraQuick can increase HIV testing and diagnosis in UK GU medicine and community settings.
Zelin
J
J
Barts Sexual Health Centre, Barts and The London NHS Trust, London EC1A 7BE. Jill.Zelin@bartsandthelondon.nhs.uk
Garrett
N
N
Saunders
J
J
Warburton
F
F
Anderson
J
J
Moir
K
K
Symonds
M
M
Estcourt
C
C
D015492:AIDS Serodiagnosis / Q000379:methods*; D000328:Adult; D000554:Ambulatory Care Facilities; D005260:Female; D015483:HIV Antibodies / Q000032:analysis*; D015658:HIV Infections / Q000175:diagnosis*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D008131:London; D008297:Male; D011237:Predictive Value of Tests; D011933:Reagent Kits, Diagnostic; D012306:Risk; D012463:Saliva / Q000276:immunology* / Q000821:virology; D012680:Sensitivity and Specificity; D013997:Time Factors; D014566:Urogenital System
D015483:HIV Antibodies; D011933:Reagent Kits, Diagnostic